Integrative Mendelian randomization reveals the soluble receptor for advanced glycation end products as protective in relation to rheumatoid arthritis.

doi:10.1038/s41598-023-35098-4

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Integrative Mendelian randomization reveals the soluble receptor for advanced glycation end products as protective in relation to rheumatoid arthritis.

Scientific reports - 17 May 2023

Lee Gha Young, Yao Chen, Hwang Shih-Jen, Ma Jiantao, Joehanes Roby, Lee Dong Heon, Ellison R Curtis, Moore Lynn L, Liu Chunyu, Levy Daniel

Abstract excerpt

Rheumatoid arthritis (RA) is a risk factor for atherosclerotic cardiovascular diseases (CVD). Given the critical roles of the immune system and inflammatory signals in the pathogenesis of CVD, we hypothesized that interrogation of CVD-related proteins using integrative genomics might provide new insights into the pathophysiology of RA. We utilized two-sample Mendelian randomization (MR) for causal inference...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Arthritis, Rheumatoid
Share to Cardiovascular Diseases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genome-Wide Association Study

Share to Glycation End Products, Advanced

Share to Mendelian Randomization Analysis

Share to Polymorphism, Single Nucleotide

Share to Receptor for Advanced Glycation End Products

Source

Open in PubMed Open full text

Identifiers

PMID: 37198231
DOI: 10.1038/s41598-023-35098-4
PMCID: PMC10192300

Provenance

PubMed metadata and Literature Corpus relationships.